Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade

Nephron. 2020;144(5):213-221. doi: 10.1159/000507305. Epub 2020 Mar 23.

Abstract

Here, we review the most recent findings on the effects of SARS-CoV-2 infection on kidney diseases, including acute kidney injury, and examine the potential effects of ARBs on the outcomes of patients with COVID-19. Lastly, we discuss the clinical management of COVID-19 patients with existing chronic renal disorders, particularly those in dialysis and with kidney transplants.

Keywords: Angiotensin receptor blockers; Angiotensin-converting enzyme inhibitors; COVID-19; Renal and cardiac side effects; SARS-CoV-2; Severe acute respiratory syndrome coronavirus.

Publication types

  • Review

MeSH terms

  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme 2
  • Angiotensin-Converting Enzyme Inhibitors
  • Angiotensins / antagonists & inhibitors*
  • Betacoronavirus / physiology
  • COVID-19
  • Coronavirus Infections / complications*
  • Humans
  • Kidney / virology
  • Kidney Diseases / complications*
  • Kidney Diseases / drug therapy*
  • Kidney Transplantation
  • Nephrologists
  • Pandemics
  • Peptidyl-Dipeptidase A
  • Pneumonia, Viral / complications*
  • Renal Dialysis
  • SARS-CoV-2
  • Virus Replication

Substances

  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Angiotensins
  • Peptidyl-Dipeptidase A
  • ACE2 protein, human
  • Angiotensin-Converting Enzyme 2